Bispecific CD40-GPC3 Antibody for Tumor-Localized Immune Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antibodies targeting CD40 for cancer treatment exhibit systemic immune activation toxicity and lack specificity, while bispecific antibodies for CD40 and other cancer antigens do not effectively activate CD40 signaling in the vicinity of cancer cells.

Innovation Solution

A bispecific antibody that specifically binds to CD40 and GPC3, with a CD40 agonistic activity only in the presence of GPC3-expressing cells, comprising an IgG portion with a direct or linker-mediated connection between heavy chain C terminus and a second antigen binding domain, utilizing specific CDR sequences for targeted CD40 and GPC3 binding.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anti-CD40 antibodies are used for cancer treatment, then CD40 signaling is activated, but systemic immune activation toxicity occurs

Engineering Contradiction:

ImproveCD40 signaling activationVSAvoidsystemic immune activation toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The bispecific antibody is designed to activate CD40 signaling locally at the tumor site by requiring simultaneous binding to both GPC3 (on cancer cells) and CD40 (on immune cells), rather than systemic activation. This spatially restricted activation reduces off-target toxicity while maintaining therapeutic efficacy.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The bispecific antibody acts as an intermediary molecule that bridges GPC3-expressing cancer cells and CD40-expressing immune cells, enabling localized immune activation only in the vicinity of tumor cells. This mediator approach confines the immune response to the tumor microenvironment.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If conventional anti-CD40 antibodies are used, then immune activation occurs, but specificity for cancer cells is lost

Engineering Contradiction:

Improveimmune activationVSAvoidcancer cell specificity

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The antibody introduces spatial specificity by requiring dual binding to GPC3 (cancer-specific) and CD40 (immune cell), thereby confining immune activation to the tumor microenvironment rather than systemic circulation.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The bispecific antibody combines two specificities (anti-GPC3 and anti-CD40) into a single molecule, enabling it to simultaneously recognize cancer cells and recruit immune cells, thereby achieving both cancer specificity and immune activation in one agent.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Measurement precision

If bispecific antibodies targeting CD40 and other cancer antigens are used, then targeting capability is improved, but CD40 signaling activation in the vicinity of cancer cells is insufficient

Engineering Contradiction:

Improvecancer antigen targetingVSAvoidCD40 signaling activation

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The invention merges the targeting function (anti-GPC3) and the immune activation function (anti-CD40) into a single bispecific antibody molecule, ensuring that CD40 signaling activation occurs only where GPC3-expressing cancer cells are present, thereby coupling targeting precision with reliable local immune activation.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12466891B2Bispecific antibody binding to CD40 and GPC3

Publication Date: 2025.11.11 KYOWA HAKKO KIRIN CO LTD

AI summary

An object of the present invention is to provide a bispecific antibody including an antigen binding domain that binds to CD40 and an antigen binding domain that binds to GPC3. The present invention relates to a bispecific antibody including an antigen binding domain that binds to CD40 and an antigen binding domain that binds to GPC3, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment, a vector containing the DNA, and the like.